专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20150282111A1 ONLINE ADAPTIVE FUSION FRAMEWORK FOR MOBILE DEVICE INDOOR LOCALIZATION 有权
标题翻译：在线自适应融合框架移动设备室内定位
公开(公告)号：US20150282111A1
公开(公告)日：2015-10-01
申请号：US14229136
申请日：2014-03-28
申请人： SHAO-WEN YANG , LEI YANG , XUE SHARON YANG
发明人： SHAO-WEN YANG , LEI YANG , XUE SHARON YANG
IPC分类号： H04W64/00 , H04W4/04
CPC分类号： H04W64/00 , G01S5/0252 , G01S5/0263 , G01S5/0278 , H04W4/04
摘要： This disclosure describes systems, methods, and computer-readable media related to employing particle filter methods to estimate the location of a mobile device. The data may include wireless data measurement associated with the mobile device and one or more access points and inertial data associated with the mobile device. Radio fingerprinting data associated with the one or more access points may be retrieved. A respective location for the wireless data measurements may be determined based on the radio fingerprinting data and inertial data. A respective weight may be calculated for the respective location for each of the plurality of particles. A respective confidence level may be maintained for the respective location for each of the plurality of particles. A current location may be identified based on the respective location for each of the plurality of particles and the respective weight associated with the respective location for each of the particles.
摘要翻译：本公开描述与使用粒子滤波器方法估计移动设备的位置相关的系统，方法和计算机可读介质。数据可以包括与移动设备相关联的无线数据测量以及与移动设备相关联的一个或多个接入点和惯性数据。可以检索与一个或多个接入点相关联的无线电指纹识别数据。可以基于无线电指纹数据和惯性数据来确定用于无线数据测量的相应位置。可以针对多个颗粒中的每个颗粒的相应位置计算相应的重量。对于多个颗粒中的每个颗粒的相应位置可以保持相应的置信水平。可以基于多个颗粒中的每一个的相应位置以及与每个颗粒的相应位置相关联的相应重量来识别当前位置。

12. 发明申请

US20150087239A1 TECHNIQUES FOR CROSS-DEVICE RADIO SIGNAL STRENGTH CALIBRATION 有权
标题翻译：用于跨设备无线电信号强度校准的技术
公开(公告)号：US20150087239A1
公开(公告)日：2015-03-26
申请号：US14038721
申请日：2013-09-26
申请人： XUE YANG , LEI YANG
发明人： XUE YANG , LEI YANG
IPC分类号： H04W24/08
CPC分类号： H04W24/08 , H04B17/26 , H04B17/318 , H04W64/00 , H04W84/12
摘要： An apparatus may include a memory to store a first radio signal strength indicator (RSSI) data set comprising first data entries for RSSI detected from a multiplicity of transmission sources by a first wireless device of a first device type, and to store a second RSSI data set comprising second data entries for RSSI detected from the multiplicity of transmission sources by a second wireless device of a second device type; and a cross-device radio calibration engine to receive the first RSSI data set and second RSSI data set and generate a cross-calibrated RSSI function comprising a function that reduces differences between the first RSSI data set and the second RSSI data set. Other embodiments are disclosed and claimed.
摘要翻译：装置可以包括存储器，用于存储由第一设备类型的第一无线设备从多个传输源检测的用于RSSI的第一数据条目的第一无线电信号强度指示符（RSSI）数据集，并且存储第二RSSI数据集合包括由第二设备类型的第二无线设备从多个传输源检测的用于RSSI的第二数据条目; 以及跨设备无线电校准引擎，用于接收第一RSSI数据集和第二RSSI数据集，并生成交叉校准的RSSI函数，其包括减少第一RSSI数据集和第二RSSI数据集之间的差异的函数。公开和要求保护其他实施例。

13. 发明申请

US20110278924A1 POWER SUPPLY CIRCUIT FOR MOTHERBOARD 失效
标题翻译：电源板供电电路
公开(公告)号：US20110278924A1
公开(公告)日：2011-11-17
申请号：US12870642
申请日：2010-08-27
申请人： HSIANG-JUI HUNG , KUN-LUNG WU , YUAN-LIN LIU , YONG-XIAN ZHAO , LEI YANG
发明人： HSIANG-JUI HUNG , KUN-LUNG WU , YUAN-LIN LIU , YONG-XIAN ZHAO , LEI YANG
IPC分类号： H02J1/00
CPC分类号： G06F1/26 , Y10T307/406
摘要： A power supply circuit for providing power and detecting a plurality of loads' input voltages on a motherboard includes a pulse width modulation (PWM) controller, a voltage output circuit and a voltage feedback circuit electrically connected to the PWM controller and the plurality of loads. The PWM controller outputs PWM control signals. The voltage output circuit receives the PWM control signals and outputs working voltage to the plurality of loads according to the received PWM control signals. The voltage feedback circuit detects the plurality of loads' input voltages and outputs feedback signals to the PWM controller according to the detected input voltages. The PWM controller adjusts its PWM control signal outputs, according to the received feedback signals, and adjusting working voltages to the plurality of loads.
摘要翻译：用于在母板上提供电力并检测多个负载的输入电压的电源电路包括脉冲宽度调制（PWM）控制器，电压输出电路和电连接到PWM控制器和多个负载的电压反馈电路。 PWM控制器输出PWM控制信号。电压输出电路接收PWM控制信号，并根据接收到的PWM控制信号向多个负载输出工作电压。电压反馈电路检测多个负载的输入电压，并根据检测到的输入电压向PWM控制器输出反馈信号。 PWM控制器根据接收到的反馈信号调整其PWM控制信号输出，并调整多个负载的工作电压。

14. 发明专利

AU2018311684A1 Methods for treating HCV 未知
公开(公告)号：AU2018311684A1
公开(公告)日：2020-02-27
申请号：AU2018311684
申请日：2018-07-20
申请人： ABBVIE INC
发明人： COLLINS CHRISTINE , FU BO , GULATI ABHISHEK , KORT JENS , KOSLOSKI MATTHEW , LEI YANG , LIN CHIH-WEI , LIU RAN , MENSA FEDERICO , NG IOK CHAN , PILOT-MATIAS TAMI , PUGATCH DAVID , SHULMAN NANCY S , TRINH ROGER , VIANI ROLANDO M , WANG STANLEY , ZHANG ZHENZHEN
IPC分类号： A61K31/454 , A61K31/4184
摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

15. 发明专利

CA2981993A1 METHODS FOR TREATING HCV 未知
公开(公告)号：CA2981993A1
公开(公告)日：2019-04-11
申请号：CA2981993
申请日：2017-10-11
申请人： ABBVIE INC
发明人： COLLINS CHRISTINE , DUMAS EMILY O , FU BO , GULATI ABHISHEK , HU YIRAN BONNIE , KORT JENS , KOSLOSKI MATTHEW , KRISHNAN PREETHI , LEI YANG , LIN CHIH-WEI , LIU RAN , MENSA FEDERICO , NG IOK CHAN , PILOT-MATIAS TAMI , PUGATCH DAVID , RHEE SUSAN , SHULMAN NANCY S , TRINH ROGER , VIANI ROLADO M , WANG STANLEY , ZHANG ZHENZHEN
IPC分类号： A61K38/06 , A61K31/4184 , A61P31/14
摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. ln one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

16. 发明专利

ZA202000943B METHODS FOR TREATING HCV 未知
公开(公告)号：ZA202000943B
公开(公告)日：2022-10-26
申请号：ZA202000943
申请日：2020-02-13
申请人： ABBVIE INC
发明人： COLLINS CHRISTINE , FU BO , GULATI ABHISHEK , KORT JENS , KOSLOSKI MATTHEW , LEI YANG , LIN CHIH-WEI , LIU RAN , MENSA FEDERICO , NG IOK CHAN , PILOT-MATIAS TAMI , PUGATCH DAVID , SHULMAN NANCY S , TRINH ROGER , VIANI ROLANDO M , WANG STANLEY , ZHANG ZHENZHEN
摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

17. 发明专利

SG11202000948QA METHODS FOR TREATING HCV 未知
公开(公告)号：SG11202000948QA
公开(公告)日：2020-02-27
申请号：SG11202000948Q
申请日：2018-07-20
申请人： ABBVIE INC
发明人： COLLINS CHRISTINE , FU BO , GULATI ABHISHEK , KORT JENS , KOSLOSKI MATTHEW , LEI YANG , LIN CHIH-WEI , LIU RAN , MENSA FEDERICO , NG IOK CHAN , PILOT-MATIAS TAMI , PUGATCH DAVID , SHULMAN NANCY S , TRINH ROGER , VIANI ROLANDO M , WANG STANLEY , ZHANG ZHENZHEN
IPC分类号： A61K31/4184 , A61K31/454
摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

18. 发明专利

AU2017248487A1 Methods for treating HCV 未知
公开(公告)号：AU2017248487A1
公开(公告)日：2019-02-21
申请号：AU2017248487
申请日：2017-10-18
申请人： ABBVIE INC
发明人： RHEE SUSAN , SHULMAN NANCY S , TRINH ROGER , VIANI ROLADO M , WANG STANLEY , ZHANG ZHENZHEN , COLLINS CHRISTINE , DUMAS EMILY O , FU BO , GULATI ABHISHEK , HU YIRAN BONNIE , KORT JENS , KOSLOSKI MATTHEW , KRISHNAN PREETHI , LEI YANG , LIN CHIH-WEI , LIU RAN , MENSA FEDERICO , NG IOK CHAN , PILOT-MATIAS TAMI , PUGATCH DAVID
IPC分类号： A61K31/498 , A61K31/4184 , A61P31/14
摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

19. 发明专利

CA3072026A1 METHODS FOR TREATING HCV 未知
公开(公告)号：CA3072026A1
公开(公告)日：2019-02-07
申请号：CA3072026
申请日：2018-07-20
申请人： ABBVIE INC
发明人： COLLINS CHRISTINE , FU BO , GULATI ABHISHEK , KORT JENS , KOSLOSKI MATTHEW , LEI YANG , LIN CHIH-WEI , LIU RAN , MENSA FEDERICO , NG IOK CHAN , PILOT-MATIAS TAMI , PUGATCH DAVID , SHULMAN NANCY S , TRINH ROGER , VIANI ROLANDO M , WANG STANLEY , ZHANG ZHENZHEN
IPC分类号： A61K38/06 , A61K31/454 , A61P31/14
摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式